Tag Archives: NS

recommended stocks to buy

Thousands are lining up at the doors…

Businesses are expecting a watershed year for profits…

recommended stocks to buy: Rogers Corporation(ROG)

Advisors’ Opinion:

  • [By Anders Bylund]

    Shares of Rogers Corp. (NYSE:ROG) gained 19.9% in April 2017, according to data from S&P Global Market Intelligence.

    So what

    The company reported first-quarter results on April 26, sending share prices nearly 12% higher the next day. Rogers saw 27% year-over-year sales growth and 79% higher earnings, leaving analyst estimates far behind in both cases.

  • [By WWW.GURUFOCUS.COM]

    For the details of Wintergreen Fund’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Wintergreen+Fund

    These are the top 5 holdings of Wintergreen FundReynolds American Inc (RAI) – 1,643,159 shares, 24.5% of the total portfolio. Consolidated-Tomoka Land Co (CTO) – 1,232,334 shares, 15.61% of the total portfolio. British American Tobacco PLC (BATS) – 782,405 shares, 12.29% of the total portfolio. Cie Financiere Richemont SA (CFR) – 286,053 shares, 5.35% of the total portfolio. Shares reduced by 15.57%Altria Group Inc (MO) – 305,421

recommended stocks to buy: Rowan Companies Inc.(RDC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Go back a year, and offshore drillers like Noble (NE), Rowan (RDC), Transocean (RIG) and Atwood Oceanics (ATW) had been all but written off–until they weren’t anymore. Since then, investors have been rewarded for picking winners in the group from the losers, as Atwood Oceanics has more than doubled, Transocean has gained 34%, and Rowan has risen 42%, while Noble and Diamond Offshore Drilling (DO) have dropped 13%.

  • [By Jon C. Ogg]

    Rowan Companies plc (NYSE: RDC) closed up 15.1% at $17.84 and the 5.2 million shares traded was just 1.3 times normal trading volume. Rowan has a consensus analyst price target of $15.04 and a 52-week trading range of $10.67 to $20.88. The company has a total market cap of $2.2 billion.

recommended stocks to buy: Atkore International Group Inc. (ATKR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.

  • [By Spencer Israel]

    3. Atkor International Group Inc (NYSE: ATKR) – Five of the six analyst ratings on the manufacturing holding company have been bullish. With the stock showing very strong technical support at $16, and currently trading at $16.68, Stockal's confidence meter is at 90%. 

recommended stocks to buy: GenMark Diagnostics, Inc.(GNMK)

Advisors’ Opinion:

  • [By Lisa Levin]

    GenMark Diagnostics, Inc (NASDAQ: GNMK) shares shot up 20 percent to $10.54. Cowen & Co. upgraded GenMark Diagnostics from Market Perform to Outperform.

recommended stocks to buy: One Horizon Group, Inc.(OHGI)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

recommended stocks to buy: Nustar Energy L.P.(NS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.

     

    Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.

     

    A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.

     

    From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.

    If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.

    Must Read: 10 Stocks George Soros Is Buying

hot penny stocks

The Trump administration’s decision to halt expedited processing of H-1B visas could abruptly disrupt the plans of thousands of immigrant workers in a range of businesses from technology to health care, immigration experts say.

H-1B visas allow employers to bring in skilled foreign workers; about 85,000 will be given out this year. The visas are in high demand and given out by lottery. It can take six months or longer for an application to be reviewed.

But the government announced Friday that, as of April 3, it will suspend the “premium processing” option, which ensures an application will be reviewed within 15 days. It costs $1,225.

Trump has accused companies of abusing the H-1B program as a way to hire foreign workers who take jobs away from Americans, at lower salaries.

The Trump administration says it’s doing away with quick-turn processing so it can sort through a large backlog of applications and try to “reduce overall H-1B processing times.”

hot penny stocks: Grifols, S.A.(GRFS)

Advisors’ Opinion:

  • [By Monica Wolfe]

    Grifols SA (GRFS)

    Paulsons fourth largest holding is in Grifols SA where he holds on to 19,786,279 shares of the companys stock. His position in the company represents 4% of his total portfolio and 5.76% of the companys shares outstanding.

hot penny stocks: Radient Technologies (RTI)

Advisors’ Opinion:

  • [By Matthew Briar]

    At first glance, a new set of rules from the Drug Enforcement Agency unveiled in the middle of December looked like it posed a problem for cannabis-newcomer Radient Technologies Inc (CVE:RTI). By assigning a controlled substances code number to ‘marijuana extract,’ simultaneously distinguishing (and acknowledging the differences of marijuana, hemp and their derivatives as Schedule I substances. As the ruling’s language explained, “This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions.”

    It presents something of an uncertainty, as it was not clear of the DEA also meant hemp and cannabis extracts when it used the term ‘marijuana extract.’ After all, the Drug Enforcement Agency has thus far done a poor job of distinguishing between hemp and marijuana, but has generally erred on the side of grouping everything as marijuana…. even if it didn’t cause a ‘high,’ and even if it did provide a medical benefit. If that was indeed the case, Radient Technologies may well be a non-starter in its quest to get into the cannabis business.

    No need to worry. Though it took weeks to get some much-needed clarification, the DEA has finally explained what it was saying two months ago. Indeed, the new ruling may actually help the medical marijuana — cannabis — along. DEA spokesman Russ Baer said in an e-mail to The Cannabist, “(The rule change) recognizes that there is a potential medical benefit to some of the cannabinoids.”

    Some still worry the wording of the law essentially, even if unintentionally, puts cannabinoids (or CBD) under the purveyance of the DEA; it’s currently not. Even so, if nothing else the ruling has the government moving towards clarity, after acknowledging CBD — the healthy version of the cannabis, and not the one that gets you high — has medical value. The next step is clarifying ho

  • [By Jim Robertson]

    Small cap Radient Technologies (CVE: RTI) is focused on extracting, isolating and purifying food/nutraceutical ingredients (colourings, flavourings, preservatives etc) and pharmaceutical raw materials from its20,000 square foot manufacturing plant in Edmonton, Alberta. The Companyworks with global brands across a range of industries (including Food and Beverage, Nutrition and Supplements, Pharmaceuticals, Personal Care and Cosmetics and Biofuel) andengageswithits clients in three distinct phases:

  • [By Matthew Briar]

    There’s an old business adage…. it’s not so much what you know, but who you know. If that’ s truly the case (and it is), then shareholders in Radient Technologies Inc (CVE:RTI) should be elated. The newest member of the Board of Directors that not already knows a lot of the right people, but has pretty much done all of things Radient would like to accomplish in the near future. That is, he was on the board for another ingredient and chemical company that was eventually acquired, but he also holds a masters degree in engineering. He can do it all, understanding the art and science of the business.

    It’s yet another reason for RTI investors to be enthused.

    Radient Technologies isn’t exactly a new company, but it’s relative notoriety is a fairly new phenomenon.

    The organization, in simplest terms, has developed an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which drives out the targeting ingredient or component much faster than more conventional extraction methods. In fact, the pressure-driven process outperforms the conventional extraction on pretty much every front. That is, the technique reduces the extraction time from hours to minutes, delivers a higher active ingredient purity, increases the recovery of actives from often scarce biomass, and uses much less solvent and energy than the more typical approach.

    The technique can, and already has, created natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics.

    The company’

  • [By Matthew Briar]

    Although the past several years have been very good ones for the cannabis — marijuana and hemp — industry, it’s still mostly being done in an old, artisan-style fashion. Most companies haven’t figured out a way of scaling up their outputs by improving their operating/production efficiency, even though the market’s growth has merited. Radient Technologies Inc (CVE:RTI) represents that next evolution of the cannabinoid business, introducing a new approach to extracting cannabinoids from cannabis plants that will not only improve yields, but create a superior, purer product.

    Canada-based Radient Technologies has developed — and patented – an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along. To fully appreciate why it matters, however, one has look at the approach other ingredients suppliers are utilizing now.

    With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated to 50 degrees Celsius (or more), and over the course of several hours, the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.

    It works, but it’s hardly ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, a lot of things you don’t want to extract can still be found in the extract, lowering the quality and purity of the ingredient.

    Radient Technologies’ microwave assisted processing changes all of this.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which

hot penny stocks: Nustar Energy L.P.(NS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.

     

    Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.

     

    A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.

     

    From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.

    If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.

    Must Read: 10 Stocks George Soros Is Buying

hot penny stocks: Neo Lithium Corp. (NTTHF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC reminds me of Critical Elements [TSXV:CRE] (OTCQX:CRECF) having five projects (CRE has 11), and also of Galaxy Resources (ASX:GXY) (OTCPK:GALXF) by being diversified across brine and spodumene and across three continents. Also some similarity with Neo Lithium’s (OTC:NTTHF) [TSXV:NLC] early stage Argentinean brine project which I recently wrote about here. However, ILC trades at a much smaller market cap of US$8m to that of Critical Elements (US$85m) or Galaxy Resources (US$724m). This is partly due to ILC giving away significant percentages of their projects, and because they are still in the early stages of development.

Top 5 Heal Care Stocks For 2018

Honing in on dividend is the best practice during market turbulence. These cash payouts are major sources of consistent income for investors when returns from the equity market are at risk.

Dividend paying stocks are primarily mature companies, which are less susceptible to large swings in the market. Their market leading position, large customer base, sustainable business model, long track of profitability and strong liquidity allow them to offer outsized payouts or sizable yields on a regular basis irrespective of the market direction.

As a result, these stocks provide greater stability and more scope for capital appreciation as opposed to those that pay high yields.

Further, a history of strong dividend growth indicates that a future hike is likely. This makes the portfolio healthy and safe.

Though these stocks have a long history of outperformance compared with the broad stock market or any other dividend paying stocks, it does not necessarily mean that they have the highest yields.

Top 5 Heal Care Stocks For 2018: Finisar Corporation(FNSR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Breaking news

    Finisar Corporation (NASDAQ: FNSR) reported in-line earnings for its fourth quarter, but issued a weak forecast for the current quarter.
    Shares of Booz Allen Hamilton Holding Corporation (NYSE: BAH) dropped around 16 percent in pre-market trading as the company reported a DoJ civil and criminal investigation regarding cost accounting and cost charging practices.
    Shares of Celsion Corporation (NASDAQ: CLSN) jumped over 110 percent in pre-market trading after withdrawing stock offering. T
    Shares of Hornbeck Offshore Services, Inc. (NYSE: HOS) surged around 17 percent in pre-market trading after the company reported a $300 million credit facility.

  • [By Leo Sun]

    Shares of fiber optic components maker Finisar (NASDAQ:FNSR) fell 17% in April due to a big third-quarter miss in mid-March. Its revenue rose 23% annually to $380.6 million, but that missed expectations by $9 million. Earnings rose136% to $0.59 per share, but that also missed estimates by three cents. Finisar’s top and bottom line guidance for the fourth quarter (16% sales growth and 83% earnings growth at the midpoints) also came in below Wall Street estimates.

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, as the stock market responded favorably to encouraging news on the employment front. The U.S. unemployment rate dropped on fairly strong job creation during the month of February, and that helped push the Dow, S&P 500, and Nasdaq Composite to modest gains of roughly between a quarter percent and a half percent. Yet even with a positive mood among market participants, some stocks weren’t able to participate in the end-of-week rally. Finisar (NASDAQ:FNSR), Zumiez (NASDAQ:ZUMZ), and Winnebago Industries (NYSE:WGO) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Finisar Corporation (NASDAQ: FNSR) reported in-line earnings for its fourth quarter, but issued a weak forecast for the current quarter. Finisar shares jumped 7.76 percent to $27.63 in the after-hours trading session.
    Shares of Booz Allen Hamilton Holding Corporation (NYSE: BAH) dropped over 13 percent in after-hours trading as the company reported a DoJ civil and criminal investigation regarding cost accounting and cost charging practices. Booz Allen shares dipped 13.30 percent to $34.10 in the after-hours trading session.
    Bob Evans Farms Inc (NASDAQ: BOBE) shares declined over 4 percent Thursday after the company reported results for its fourth quarter. The company posted better-than-expected Q4 earnings, while sales missed estimates. Bob Evans shares dropped 4.26 percent to close at $68.99 on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

Top 5 Heal Care Stocks For 2018: (LGF.A)

Advisors’ Opinion:

  • [By Keith Noonan]

    While 2016 played host to a range of films that underperformed, the biggest flops belonged to Disney (NYSE:DIS), Viacom (NASDAQ:VIA) (NASDAQ:VIAB) and Lions Gate Entertainment (NYSE:LGF.A). Click through the presentation below to get the details on the year’s five biggest film flops and to learn what last year’s movie misfires mean for the companies involved.

Top 5 Heal Care Stocks For 2018: Nustar Energy L.P.(NS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.

     

    Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.

     

    A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.

     

    From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.

    If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.

    Must Read: 10 Stocks George Soros Is Buying

Top 5 Heal Care Stocks For 2018: Panhandle Royalty Company(PHX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Energy sector was the top gainer in the US market on Friday. Top gainers in the sector included Superior Energy Services, Inc. (NYSE: SPN), Panhandle Oil and Gas Inc. (NYSE: PHX), and SM Energy Co (NYSE: SM).

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

Top 5 Heal Care Stocks For 2018: SM Energy Company(SM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

  • [By Lisa Levin]

    Energy sector was the top gainer in the US market on Monday. Top gainers in the sector included Helix Energy Solutions Group Inc (NYSE: HLX), SM Energy Co (NYSE: SM), and Ecopetrol SA (ADR) (NYSE: EC).

  • [By Lisa Levin]

    Energy sector was the top gainer in the US market on Friday. Top gainers in the sector included Superior Energy Services, Inc. (NYSE: SPN), Panhandle Oil and Gas Inc. (NYSE: PHX), and SM Energy Co (NYSE: SM).

  • [By Lisa Levin]

    On Wednesday, the energy sector proved to be a source of strength for the market. Leading the sector was strength from SM Energy Co (NYSE: SM) and W&T Offshore, Inc. (NYSE: WTI).

us stock exchange

Social Security retirement benefits are designed to replace about 40% of the average American worker’s earnings. However, the benefit formula is weighted in favor of lower-income workers and tends to replace less of higher earners’ pre-retirement income. With that in mind, let’s look at how much your Social Security benefit could be if you earn $100,000 per year throughout your career, which is on the higher end of the maximum earnings considered for Social Security benefits.

How the Social Security retirement benefit formula works

Your Social Security benefit is determined by your entire work record. Every year’s earnings of your entire career are indexed for inflation, and then the 35 highest are considered when calculating your benefit. If you don’t have 35 years of earnings, zeros will be used for the remaining years.

Image source: Getty Images.

us stock exchange: Nordson Corporation(NDSN)

Advisors’ Opinion:

  • [By Monica Gerson]

    Nordson Corporation (NASDAQ: NDSN) is estimated to post its quarterly earnings at $0.92 per share on revenue of $415.52 million.

    KLX Inc (NASDAQ: KLXI) is projected to report its quarterly earnings at $0.30 per share on revenue of $383.62 million.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on GlaxoSmithKline (GSK) , Chubb (CB) , XPO Logistics (XPO) , FedEx (FDX) and Nordson (NDSN) .

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

  • [By Steve Symington]

    Nordson Corporation (NASDAQ:NDSN) released fiscal second-quarter 2017 results on Monday that easily exceeded expectations, highlighting broad-based organic growth and solid contributions from its recently acquired businesses.

  • [By Monica Gerson]

    Nordson Corporation (NASDAQ: NDSN) is projected to post its quarterly earnings at $0.92 per share on revenue of $415.52 million. Nordson shares gained 0.88 percent to close at $75.74 on Friday.

us stock exchange: Hostess Brands, Inc. (TWNK)

Advisors’ Opinion:

  • [By Paul Ausick]

    There was an IPO of sorts last week when Gores Holdings II raised $375 million with an offer of 37.5 million units at $10 per unit. The shares are listed on the Nasdaq under the ticker symbol GSHTU. Gores Holdings I acquired Hostess Brands last year and completed an IPO in December for Hostess Brands Inc. (NASDAQ: TWNK).

us stock exchange: Array BioPharma Inc.(ARRY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.43 percent in trading on Friday. Meanwhile, top gainers in the sector included DexCom, Inc. (NASDAQ: DXCM), and Array Biopharma Inc (NASDAQ: ARRY).

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto

us stock exchange: Insys Therapeutics, Inc.(INSY)

Advisors’ Opinion:

  • [By William Patalon III]

    Insys Therapeutics Inc. (NASDAQ: INSY) – our “War on Pain” biotech play – has given us a profit of more than 16% since we recommended the stock just two weeks ago.

  • [By Peter Graham]

    Small cap Insys Therapeutics (NASDAQ: INSY) is the seventh most shorted stock on the Nasdaq with short interest of 43.97% according to Highshortinterest.com. Insys Therapeutics is a small cap specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids,the Companyis developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS庐 (fentanyl sublingual spray), CII, and SYNDROS庐 (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol.The Company aims to developmedications for potentially treating addiction to opioids, opioid overdose, epilepsy and other disease areas with a significant unmet need.

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell by 0.20 percent. Meanwhile, top losers in the sector included Horizon Pharma PLC (NASDAQ: HZNP), down 20 percent, and Insys Therapeutics Inc (NASDAQ: INSY), down 17 percent.

  • [By Sean Williams]

    Shares of Insys Therapeutics (NASDAQ:INSY), a biopharmaceutical company that develops medicines to treat pain and other supportive-care products, tumbled by as much as 11% during Wednesdays trading session before recovering to finish lower by less than 2%. The reason for the volatile trading can probably be traced to carryover from the company’s first-quarter earnings release before the opening bell on Tuesday.

us stock exchange: Nustar Energy L.P.(NS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.

     

    Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.

     

    A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.

     

    From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.

    If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.

    Must Read: 10 Stocks George Soros Is Buying

us stock exchange: Coherent, Inc.(COHR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Rofin-Sinar Technologies (NASDAQ: RSTI) got a boost, shooting up 37 percent to $31.50 as Coherent, Inc. (NASDAQ: COHR) announced its plans to buy Rofin-Sinar Technologies Inc in a deal valued at around $942 million.